Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

BioCorRx, Inc. (BICX) Targeting Alcohol and Opioid Addiction with Innovative Two-Pronged Approach

BioCorRx (OTCQB: BICX) is the owner and creator of an innovative addiction Treatment program used by a network of independent treatment centers to improve the lives of their patients struggling with alcohol and opioid addictions. The BioCorRx® Recovery Program leverages an innovative, two-pronged approach that addresses the underlying physical and behavioral issues associated with these addictions. The first half of this approach relies on a highly effective, proprietary implant formulation of the FDA-approved medication naltrexone, for which Biocorrx holds worldwide license rights (excluding Australia and New Zealand). The second half focuses on a modular counseling program coupled with overlapping peer support that is tailored specifically for those afflicted with alcohol and opioid addictions, helping to prepare them both physically and mentally for a life without these often dangerous substances.

America’s opioid epidemic is an increasingly treacherous issue that affects millions of people across the country. Per data from the Centers for Disease Control and Prevention, more than half a million people in the United States died from drug overdose from 2000 to 2015. Of those, more than 60 percent were linked to an opioid. Likewise, deaths from prescription opioids have more than quadrupled since 1999, driven by a nearly identical spike in the amount of prescription opioids sold. The negative implications associated with this addiction include traumatic life events for the addicted and their loved ones, as well as monumental financial expense. A 2010 study conducted by the American Society of Addiction Medicine found that addiction costs an estimated $700 billion annually in the U.S. alone.

Treating this growing problem has proven difficult. In 2011, the Substance Abuse and Mental Health Services Administration reported that 23.5 million persons aged 12 or older, roughly 9.3 percent of the population, needed treatment for an illicit drug or alcohol abuse problem. Of those, only 11.2 percent received the vital treatment at a specialty facility. BioCorRx aims to close this gap by both operating specialty facilities to aid those in need and providing a more thorough treatment program that’s been shown to lower patient drop-out rates, due to reduced cravings, and increase compliance rates, through automatic medication delivery and discreet outpatient treatment options.

In recent months, BioCorRx, through its BioCorRx Pharmaceuticals subsidiary, has looked to continue building on this proven medication through the clinical development of BICX101, a sustained release, injectable naltrexone for the treatment of opioid and alcohol use disorders. In early April, the company announced that three different formulations of the drug candidate showed success in reaching 28 days of sustained release in its preclinical studies, including one with an injection volume of just one milliliter. Following this result, BioCorRx formally requested a pre-IND meeting with the U.S. Food and Drug Administration as it continues to conduct additional studies in order to compile more data points.

In a business update issued earlier this month, Lourdes Felix, CFO, COO and director of BioCorRx, noted the strength of the company’s balance sheet following a March equity financing of $940,000 with accredited investors, as well as an investment of $1.7 million from Alpine Creek Capital Partners. Capital stemming from these transactions is expected to allow BioCorRx to continue executing on its business plan, including completion of “a few rounds of preclinical studies of BICX101” and accelerated sales and marketing activities related to its BioCorRx Recovery Program.

A strong balance sheet isn’t the only aspect of BioCorRx’s growth strategy about which prospective shareholders should be particularly optimistic. On May 16, the company announced its submission of a listing application for the Nasdaq Capital markets. The move comes less than two months after OTC Markets Group (OTCQX: OTCM) welcomed BioCorRx to the OTCQB Venture Market, which it reserves for early-stage and developing companies that are current in their reporting and undergo an annual verification and management certification process. The company will be required to meet a number of Nasdaq listing requirements in order to complete the uplist, but CFO Felix noted that members of BioCorRx’s management team “look forward to the prospect of a NASDAQ listing,” which they anticipate will “enhance BioCorRx’s visibility in the Investment Community to a larger market and provide for a broader, more diverse base of shareholders.”

Addressing the growing opioid epidemic in the United States, as well as lingering alcohol addiction issues, represents both an urgent call to action and a sizable market opportunity for companies offering proven effective treatment options. BioCorRx, through its innovative non-addictive medication-assisted treatment (MAT) program and promising clinical pipeline, represents an opportunity for the investment community to participate in the resolution of this crisis while capitalizing on the growth prospects of a leading edge health care solutions company.

For more information, visit

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
480.374.1336 Office
[email protected]

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished:

This post first appeared on Monaker Group, Inc. (MKGI) Carves Niche In Explosi, please read the originial post: here

Share the post

BioCorRx, Inc. (BICX) Targeting Alcohol and Opioid Addiction with Innovative Two-Pronged Approach


Subscribe to Monaker Group, Inc. (mkgi) Carves Niche In Explosi

Get updates delivered right to your inbox!

Thank you for your subscription